<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part4">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>4</PartID>
        <PartNumber>Part III</PartNumber>
        <PartSequenceNumber>4</PartSequenceNumber>
        <PartTitle>Angiogenesis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap19" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>19</ChapterID>
          <ChapterNumber>Chapter 19</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_19</ChapterDOI>
          <ChapterSequenceNumber>19</ChapterSequenceNumber>
          <ChapterTitle Language="En">Thalidomide and Analogs</ChapterTitle>
          <ChapterFirstPage>215</ChapterFirstPage>
          <ChapterLastPage>223</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>4</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Erin</GivenName>
                <GivenName>R.</GivenName>
                <FamilyName>Gardner</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Giuseppe</GivenName>
                <Particle>Di</Particle>
                <FamilyName>Lorenzo</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_19" CorrespondingAffiliationID="Aff1_19">
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <GivenName>D.</GivenName>
                <FamilyName>Figg</FamilyName>
              </AuthorName>
              <Contact>
                <Email>wdfigg@helix.nih.gov</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_19">
              <OrgDivision>Medical Oncology Branch, National Cancer Institute</OrgDivision>
              <OrgName>NIH</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_19" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Thalidomide (Thalomid<Superscript>®</Superscript>), originally marketed as a sedative in Europe in the 1950s but withdrawn after teratogenicity was observed, has experienced a resurgence of interest due to its apparent anti-angiogenic and immunomodulatory properties. Thalidomide is currently in clinical testing for the treatment of prostate cancer. Numerous studies that have been completed, or are currently ongoing, have demonstrated promising activity. Thalidomide has been tested as a single agent and in combination with both targeted agents, such as bevacizumab, and traditional cytotoxic drugs, such as paclitaxel and docetaxel, in the majority of the studies. A range of thalidomide analogs have been generated in an effort to improve the clinical activity while reducing the side effect profile. Lenalidomide (Revlimid<Superscript>™</Superscript>), an immunomodulatory analog of thalidomide, has entered clinical trials in prostate cancer and is being tested in many of the same combinations. This chapter reviews the clinical trials of thalidomide and lenalidomide initiated or completed to date, including dosing, clinical response, and toxicity.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Thalidomide</Keyword>
            <Keyword>Lenalidomide</Keyword>
            <Keyword>Angiogenesis</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Immunomodulatory</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Thalidomide was originally developed by the German company Chemie Gruenthal in the 1950s as an oral sedative and was widely prescribed outside of the US for off-label usage as an antiemetic. It was withdrawn from the market in 1961 after thalidomide was found to be teratogenic, causing phocomelia in over 10,000 babies, whose mothers had taken the drug during their first trimester of pregnancy [<CitationRef CitationID="CR1_19">1</CitationRef>].</Para>
            <Para TextBreak="No">Over 30 years later, a resurgence of interest in thalidomide occurred when D’Amato et al. reported that it was an inhibitor of angiogenesis [<CitationRef CitationID="CR2_19">2</CitationRef>]. They postulated that the observed limb defects were directly caused by inhibition of blood vessel growth in the developing fetal limb bud and demonstrated that thalidomide inhibits blood vessel growth in the chicken chorioallantoic membrane assay and inhibits bFGF-stimulated corneal neovascularization in treated rabbits. Interestingly, thalidomide is believed to exert its anti-angiogenic effects only when metabolized, as reported by several groups, though the exact mechanism of action has not been elucidated [<CitationRef CitationID="CR2_19">2</CitationRef>, <CitationRef CitationID="CR3_19">3</CitationRef>]. In addition to its anti-angiogenic activity, thalidomide has also been shown to inhibit COX-2 and have immunomodulatory and anti-inflammatory activity [<CitationRef CitationID="CR4_19">4</CitationRef>].</Para>
            <Para TextBreak="No">The observed anti-angiogenic activity of thalidomide is of particular interest for the treatment of prostate cancer and other solid tumors. Numerous studies have shown that tumor angiogenesis correlates with both early hormone-dependent prostate growth and development of metastatic tumors [<CitationRef CitationID="CR5_19">5</CitationRef>–<CitationRef CitationID="CR7_19">7</CitationRef>].</Para>
            <Para TextBreak="No">In late 1997, thalidomide (marketed as Thalomid<Superscript>®</Superscript>, by Celgene Corp.) was granted the US Food and Drug Administration (FDA) approval for the treatment of erythema nodosum leprosum, a serious skin complication of leprosy. In 2006, thalidomide was granted the accelerated FDA approval for the treatment of multiple myeloma, in combination with dexamethasone.</Para>
            <Para TextBreak="No">Because of the severe teratogenicity of thalidomide, all distribution is heavily restricted and monitored, under Celgene’s S.T.E.P.S. program (System for Thalidomide Education and Prescribing Safety) [<CitationRef CitationID="CR8_19">8</CitationRef>]. This program was designed to minimize the chance of fetal exposure, and requires prescribers and pharmacists to register with the program. For male patients, the program involves extensive counseling about the risks and benefits, along with requirements for taking the drug. Additionally, male patients are instructed to use a latex condom during sexual intercourse, regardless of vasectomy, because of the presence of thalidomide in semen.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Thalidomide as a Single Agent</Heading>
            <Para TextBreak="No">On the basis of the anti-angiogenic activity of thalidomide reported by D’Amato et al., and the numerous publications linking angiogenesis with prostate cancer progression, an open-label, randomized Phase II study of thalidomide was initiated at the National Cancer Institute [<CitationRef CitationID="CR9_19">9</CitationRef>]. This study enrolled a total of 63 men with castration-resistant prostate cancer (CRPC), 50 of which received 200 mg/day (the low-dose arm) and 13 of which received 1,200 mg/day (the high-dose arm). The high-dose arm was poorly tolerated, and many patients could not be escalated above 200 mg/day owing to the side effects, primarily sedation and fatigue. This arm was terminated early, as none of the 13 patients had a &gt;50% decline in prostate-specific antigen (PSA). However, a total of 28% of patients had a &gt;40% decline in PSA. Four patients maintained a &gt;50% decline in PSA for more than 150 days. This is of note considering that thalidomide has been shown to upregulate the expression of PSA in prostate cancer cells [<CitationRef CitationID="CR10_19">10</CitationRef>]. However, by computed tomography (CT) or bone scan criteria, there were no partial responses (PR). Microvessel count and the expression of angiogenic markers (vascular endothelial growth factor, VEGF, and basic fibroblast growth factor, bFGF) were also evaluated in biopsy samples, although a correlation with response was not observed. Conversely, circulating bFGF did appear to decrease in patients who received the drug for more than 4 months. Figg et al. reported that constipation, dizziness, edema, fatigue, mood changes were the most prevalent toxicities observed [<CitationRef CitationID="CR9_19">9</CitationRef>]. Molloy et al. published detailed information about the development of thalidomide-induced neuropathy in this trial [<CitationRef CitationID="CR11_19">11</CitationRef>]. Of the eight patients remaining on study at 6 months, three patients had clinical and electrophysiologic evidence of sensory neuropathy. The three patients who remained on study after 9 months of treatment had all developed symptoms of peripheral neuropathy since the previous examination [<CitationRef CitationID="CR11_19">11</CitationRef>].</Para>
            <Para TextBreak="No">A second open-label Phase II study of thalidomide as a single agent was subsequently reported by Drake et al. [<CitationRef CitationID="CR12_19">12</CitationRef>]. Twenty men with CRPC received 100 mg/day thalidomide for up to 6 months. A &gt;50% decline in PSA was observed in three (15%) of the treated men. A correlation between PSA and serum bFGF and VEGF was observed, with 5 of the 6 men whose PSA declined also exhibiting a decrease in circulating bFGF and VEGF. Similar to the initial study published by Figg et al., the most commonly observed adverse effects were constipation, fatigue (“sedation hangover”), and dizziness. Although these side effects were generally mild, all seven of the men who completed 6 months of thalidomide therapy exhibited subclinical peripheral neuropathy.</Para>
            <Para TextBreak="No">Both the Figg and Drake studies enrolled patients with CRPC, a population that has typically been heavily pretreated and has significant tumor burden. However, as angiogenesis inhibitors are anticipated to be cytostatic, halting tumor progression rather than resulting in regression, it has been hypothesized that treatment earlier in the course of the disease process would be more beneficial. Recently, a double-blind randomized crossover Phase III study of thalidomide vs. placebo control in patients with stage D0 androgen-dependent prostate cancer following limited hormonal ablation was completed [<CitationRef CitationID="CR13_19">13</CitationRef>]. The study enrolled 159 patients and after 6 months of intermittent GnRH agonist treatment (with leuprolide or goserelin), therapy with thalidomide (200 mg/day) or placebo was initiated. The median time to PSA progression for the thalidomide group was 17.1 months vs. 6.6 months on placebo (<Emphasis Type="Italic">p</Emphasis>= 0.0002). Despite thalidomide having no effect on testosterone normalization, there was a clear effect on PSA progression. Neuropathy was evident with prolonged use of thalidomide.</Para>
            <Para TextBreak="No">Much interest is focused on the role of the tumor microenvironment and how interruption of the interaction between the tumor and its surrounding normal stroma may result in inhibition of tumor progression. Efstathiou et al. evaluated the effect of thalidomide on the tumor microenvironment by treating 18 men with 200–600 mg/day for 12 weeks immediately prior to radical prostatectomy [<CitationRef CitationID="CR14_19">14</CitationRef>]. All patients were started at a dosage of 200 mg/day and the dose was then escalated to 600 mg/day in the absence of grade 3 or 4 toxicity. Serum PSA levels declined in 17 of the 18 men enrolled, with a median reduction of 42% after 12 weeks of treatment. Similar to previous studies, the most frequent toxicities observed were low-grade somnolence, fatigue, neurotoxicity, and constipation. Following radical prostatectomy, thalidomide-treated prostate tissue was compared with untreated match-control prostate tissue using microarrays. VEGF and interleukin-6 (IL-6), both of which are involved in prostate cancer angiogenesis, were significantly lower in the thalidomide treated group, in both the tumor epithelium and the stroma. Significantly decreased expression of Smoothened (Smo), a key component of the sonic hedgehog signaling pathway was observed, as was a decrease in the matrix metalloproteinases (MMPs), MMP-2 and MMP-9 expression, in thalidomide-treated tissue when compared with control. These observations suggest that thalidomide is affecting the tumor microenvironment in a manner that may result in a decrease in the invasiveness of the tumor phenotype [<CitationRef CitationID="CR14_19">14</CitationRef>]. Table <InternalRef RefID="Tab1">19.1</InternalRef> provides a summary of single agent thalidomide trials in men with prostate cancer.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 19.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Summary of single agent thalidomide trials in prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Investigator</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Patients enrolled</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Dose</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Clinical results</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Major toxicities</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Figg et al. [<CitationRef CitationID="CR9_19">9</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>63 men with CRPC (50 low-dose and 13 high-dose)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200 mg/day (low-dose) or 1,200 mg/day (high-dose)</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>28% of patients &gt;40% PSA decline</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Sedation, fatigue, constipation, dizziness, edema, mood changes, neuropathy</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Drake et al. [<CitationRef CitationID="CR12_19">12</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>20 men with CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>100 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>15% of patients &gt;50% PSA decline</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Constipation, fatigue, dizziness, peripheral neuropathy</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Figg et al. [<CitationRef CitationID="CR13_19">13</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>159 men with stage D0 androgen-dependent disease (randomized crossover)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Median time to PSA progression 17.1 months vs. 6.6 with placebo</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Standard toxicities, neuropathy</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Efstathiou et al. [<CitationRef CitationID="CR14_19">14</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>18 men with prostate cancer, prior to radical prostatectomy</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200–600 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>PSA decline in 17/18 mean enrolled (median of 42% decline after 12 weeks of treatment)</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Somnolence, fatigue, neurotoxicity, and constipation</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">CRPC</Emphasis> castration-resistant prostate cancer; <Emphasis Type="Italic">PSA</Emphasis> prostate-specific antigen</SimplePara>
                </tfooter>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Thalidomide in Combination Therapy</Heading>
            <Para TextBreak="No">In 2004, docetaxel (Taxotere<Superscript>®</Superscript>), a traditional cytotoxic agent, was approved in combination with prednisone for advanced CRPC, based on the improved overall survival when compared with mitoxantrone plus prednisone [<CitationRef CitationID="CR15_19">15</CitationRef>]. Docetaxel had previously been shown to have activity in CRPC both as a single agent and in combination with estramustine [<CitationRef CitationID="CR16_19">16</CitationRef>–<CitationRef CitationID="CR18_19">18</CitationRef>]. In 1999, a randomized Phase II clinical study compared thalidomide plus weekly docetaxel with weekly docetaxel alone as first-line treatment in men with CRPC [<CitationRef CitationID="CR19_19">19</CitationRef>]. Twenty-five men were randomized to receive 30 mg/m<Superscript>2</Superscript> docetaxel intravenously each week for 3 out of 4 weeks. Fifty men were randomized to the same regimen with the addition of 200 mg daily oral thalidomide. At a median follow-up time of 26.4 months, the proportion of patients with &gt;50% decline in PSA was higher in the combination group (53% in the docetaxel/thalidomide group compared with 37% for docetaxel alone). In addition, overall survival at 18 months was greater in the combination treatment arm when compared with docetaxel alone (68.2% vs. 42.9%). Median progression-free survival (PFS) was also longer in the docetaxel/thalidomide cohort (5.9 months when compared with 3.7 months). However, none of these findings were statistically significant. The majority of observed toxicities were expected based on earlier studies of these two agents. However, of serious concern was the observation that 12 of the first 43 patients in the docetaxel/thalidomide cohort experienced thromboembolic events, either venous thrombosis, transient ischemic attack, or stroke. Conversely, none of the patients receiving docetaxel alone experienced thromboembolic events. The addition of low-molecular-weight heparin (LMWH) to the combination regimen prevented any further events from occurring [<CitationRef CitationID="CR19_19">19</CitationRef>].</Para>
            <Para TextBreak="No">Numerous subsequent studies continued to combine thalidomide with traditional cytotoxic chemotherapy. One study added estramustine to the combination of doctetaxel and thalidomide described earlier, based on the synergistic activity of estramustine with docetaxel and promising preclinical activity of this triple combination [<CitationRef CitationID="CR20_19">20</CitationRef>]. A total of 20 patients with metastatic CRPC were enrolled into this phase II clinical trial. PFS was 7.2 months and 18 of the patients had a &gt;50% decline in PSA. Two of the 10 patients with soft-tissue lesions had a partial response based on CT scan. The majority of patients (17/20) required a dose reduction of at least one of the three agents, and 65% of patients experienced grade 3 or 4 toxicities. On the basis of the incidence of thromboembolic events in the initial docetaxel-thalidomide trial, LMWH was administered to all patients. Despite this prophylactic treatment, two patients experienced thromboembolic events [<CitationRef CitationID="CR19_19">19</CitationRef>]. Based on the results of this trial, a larger, randomized study is required to confirm that the addition of thalidomide to the combination of docetaxel and estramustine is warranted.</Para>
            <Para TextBreak="No">The same regimen was also tested in a community-based study of elderly men, using 100–200 mg/day thalidomide [<CitationRef CitationID="CR21_19">21</CitationRef>]. Ten of 17 patients (59%) experienced a PSA decline of &gt;50%, with one PR and seven stable disease (SD) by RECIST criteria. Following 6 months of treatment, those responding or with SD switched over to maintenance thalidomide only. Overall, three patients experienced life threatening deep vein thrombosis (despite warfarin prophylaxis), and more than half of the patients receiving 200 mg/day thalidomide required dose reductions. The authors concluded that in elderly men with CRPC, this combination did not represent an improvement over the previously reported efficacy of docetaxel or estramustine, especially in light of the apparent toxicity [<CitationRef CitationID="CR21_19">21</CitationRef>].</Para>
            <Para TextBreak="No">A similar study was performed by Mathew et al. that combined thalidomide and estramustine with another taxane, paclitaxel [<CitationRef CitationID="CR22_19">22</CitationRef>]. The trial was designed as a Phase I/II, to establish the maximum tolerated dose (MTD) of thalidomide, when used in this combination. The MTD was established at 600 mg/day, in combination with 100 mg/m<Superscript>2</Superscript> paclitaxel (days 3 and 10) and 140 mg estramustine (three times daily on days 1–5 and 8–12). However, the majority of patients could not be escalated beyond 400 mg/day thalidomide, because of the somnolence or fatigue. Regardless, 76% of evaluable patients experienced &gt;50% decline in PSA, with 5 of 18 patients with measurable disease exhibiting an objective response. Interestingly, 64% of the patients with disease refractory to previous taxane therapy had &gt;50% decline in PSA. The overall median time to progression was 3 months and median survival duration was 13.6 months. Grade 3/4 toxicities included neutropenia, fatigue, dyspnea, and thromboembolic events (despite prophylactic low-dose warfarin and aspirin). Because of the early and cumulative toxicity observed with thalidomide, Mathew et al. recommended future dosing of thalidomide in this combination not to exceed 200 mg/day.</Para>
            <Para TextBreak="No">The use of low-dose thalidomide in combination therapy was also confirmed in a small Phase I study evaluating thalidomide and paclitaxel in combination with doxorubicin in men with CRPC [<CitationRef CitationID="CR23_19">23</CitationRef>]. The thalidomide dose was escalated from 200 to 400 mg/day, and the MTD was determined to be 300 mg/day. This regimen also proved to be efficacious in this heavily pretreated population. All nine patients evaluable for response experienced at least SD, with 5 of the 9 having PSA declines of &gt;50%. Neutropenia was the most common grade 3/4 toxicity, occurring in 9 of the 12 patients across all dose levels [<CitationRef CitationID="CR23_19">23</CitationRef>]. A Phase II study at the University of Pittsburgh is currently underway, evaluating thalidomide and doxorubicin, without paclitaxel, in men with CRPC [<CitationRef CitationID="CR24_19">24</CitationRef>].</Para>
            <Para TextBreak="No">Romero et al. recently investigated the oral combination of dexamethasone and thalidomide in patients with CRPC, who had progressed after chemotherapy [<CitationRef CitationID="CR25_19">25</CitationRef>]. Steroid-only treatments (prednisone, hydrocortisone, or dexamethasone) had previously exhibited some activity in CRPC [<CitationRef CitationID="CR26_19">26</CitationRef>–<CitationRef CitationID="CR31_19">31</CitationRef>]. In this study of 39 men, median PFS was 84 days. Ten individuals (26%) had at least a 50% decline in PSA with no radiological or clinical progression. An additional 14 individuals exhibited a decline in PSA, but had other progression by 12 weeks. In addition to poor efficacy, this regimen resulted in five thromboembolic events and significant neuropathy [<CitationRef CitationID="CR25_19">25</CitationRef>].</Para>
            <Para TextBreak="No">A phase I study by Di Lorenzo et al. evaluated the combination of thalidomide and cyclophosphamide in 16 highly pretreated men with CRPC [<CitationRef CitationID="CR32_19">32</CitationRef>]. The MTD of thalidomide was found to be 100 mg/day, because of one incident each of grade 3 peripheral neuropathy and venous thrombosis in the 200 mg/day cohort. This low MTD is perhaps unsurprising considering that it has previously been reported that cyclophosphamide alters the pharmacokinetics of thalidomide, prolonging the half-life and increasing drug exposure [<CitationRef CitationID="CR33_19">33</CitationRef>]. In this heavily pretreated population, only 2 of 13 evaluable patients had a decline in PSA &gt;50% [<CitationRef CitationID="CR32_19">32</CitationRef>].</Para>
            <Para TextBreak="No">The combination of thalidomide and granulocyte stimulating factor (GM-CSF) was initially evaluated in 22 men with CRPC, based on the observed single agent activity of these two therapies [<CitationRef CitationID="CR34_19">34</CitationRef>]. Patients received GM-CSF three times weekly, and oral thalidomide dose was escalated up to 200 mg/day. All patients experienced a decline in PSA, with five patients (23%) exhibiting a decrease of &gt;50%. Furthermore, two patients achieved an objective reduction in measurable soft tissue disease [<CitationRef CitationID="CR34_19">34</CitationRef>]. This relatively well-tolerated regimen was subsequently evaluated in a Phase II study enrolling patients with hormone-naïve disease [<CitationRef CitationID="CR35_19">35</CitationRef>]. Thalidomide was initially administered at 100 mg/day, and escalated up to 400 mg/day based on individual tolerance. Of 20 evaluable patients, 18 experienced a decline in PSA (median of 59%, range 26–89%). The median duration of response was 11 months [<CitationRef CitationID="CR35_19">35</CitationRef>]. A subsequent study was initiated by the same investigators, adding docetaxel to the thalidomide and GM-CSF regimen in patients with hormone-naïve prostate cancer, but has since been terminated [<CitationRef CitationID="CR36_19">36</CitationRef>].</Para>
            <Para TextBreak="No">Laber et al. reported the results of a Phase I study of thalidomide, capecitabine, and temozolomide that included two patients with advanced prostate cancer [<CitationRef CitationID="CR37_19">37</CitationRef>]. Thalidomide was administered at 100 mg/day. Both of the men with prostate cancer experienced a partial response, suggesting that this regimen may warrant further study.</Para>
            <Para TextBreak="No">Finally, a promising phase II trial combining thalidomide with bevacizumab (to block multiple antiangiogenic pathways) along with docetaxel and prednisone is currently underway [<CitationRef CitationID="CR38_19">38</CitationRef>]. Thalidomide (200 mg) and prednisone (10 mg) are being administered daily, with docetaxel (75 mg/m<Superscript>2</Superscript>) and bevacizumab (15 mg/kg) given every 3 weeks. A total of 60 patients with metastatic mCRPC have been enrolled. Ninety percent of patients receiving the combination therapy had PSA declines of ≥ 50%, and 88% achieved a PSA decline of ≥ 30% within the first 3 months of treatment. The median time to progression was 18.3 months with a median overall survival of 28.2 months [38]. The addition of bevacizumab and thalidomide to docetaxel is an active combination with manageable toxicities and future studies are warranted in this patient population. Table <InternalRef RefID="Tab2">19.2</InternalRef> summarizes the completed clinical trials of thalidomide combinations in prostate cancer.<Table Float="Yes" ID="Tab2">
                <Caption Language="En">
                  <CaptionNumber>Table 19.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Summary of completed thalidomide combination trials in prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="6">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <colspec colname="c6" colnum="6"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Investigator</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Patients enrolled</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Thalidomide dose</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Combination agents</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Clinical Results</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Major toxicities</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Dahut et al. [<CitationRef CitationID="CR19_19">19</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>75 men with CRPC (50 randomized to combination, 25 to docetaxel alone)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>30 mg/m<Superscript>2</Superscript> docetaxel weekly</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>No statistically significant findings. Overall survival at 18 months: 68.2% vs. 42.9% for docetaxel alone. Median PFS: 5.9 months vs. 3.7 months for docetaxel alone</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Fatigue, edema, constipation, sensory neuropathy. High incidence of thromboembolic events led to addition of prophylactic LMWH</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Figg et al. [<CitationRef CitationID="CR20_19">20</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>20 men with metastatic CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>30 mg/m<Superscript>2</Superscript> docetaxel weekly on days 1, 8 and 15, plus estramustine (3×/day on days 1–3, 8–10, and 15–17 of each 28-day cycle)</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PFS of 7.2 months. PSA decline of &gt;50% in 18/20 patients. Two PR in patients with soft tissue lesions</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>17/20 patients required dose reductions in 1 or more drug. Nausea, sedation, constipation, alopecia, sensory neuropathy. 2 thrombotic events, despite prophylactic anticoagulation</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Frank et al. [<CitationRef CitationID="CR21_19">21</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>17 elderly men with CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>100–200 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>25 mg/m<Superscript>2</Superscript> docetaxel weekly on days 1, 8, and 15, plus 140 mg estramustine 3×/day, 3× per week</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 10/17 patients. 1 PR, 7 SD. Median survival of 17 months</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Major grade 3/4 toxicities included: DVT, asthenia, edema and dyspnea. More than half of the patients required dose reductions of thalidomide from 200 mg</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Mathew et al. [<CitationRef CitationID="CR22_19">22</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>40 men with CRPC (10 Phase I + 30 Phase II)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200–600 mg/day (600 established as thalidomide MTD)</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>100 mg/m<Superscript>2</Superscript> paclitaxel on days 3 and 10, 140 mg estramustine 3×/day on days 1–5 and 8–12 of 21-day cycle</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 29/38 patients. Objective response in 5/18 patients with measurable disease</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Major grade 3/4 toxicities included: neutropenia, fatigue, dyspnea and thromboembolic events</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Amato and Sarao [<CitationRef CitationID="CR23_19">23</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>12 men with CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>200–400 mg/day (300 established as thalidomide MTD)</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>100 mg/m<Superscript>2</Superscript> paclitaxel and 20 mg/m<Superscript>2</Superscript> doxorubicin weekly for 3 weeks of each 5 week cycle</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 5/9 evaluable patients</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Major grade 3/4 toxicities included: neutropenia, fatigue, constipation and leukopenia</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Romero et al. [<CitationRef CitationID="CR25_19">25</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>39 men with CRPC, following one or more cytotoxic treatment</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>100–400 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>0.75 mg dexamethasone twice daily</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 10/39 patients. Median PFS: 84 days</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Major grade 3/4 toxicities included: neuropathy, thrombotic events and fatigue</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Di Lorenzo et al. [<CitationRef CitationID="CR32_19">32</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>16 men with CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>100–200 mg/day (100 established as MTD)</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>50 mg/day oral cyclophosphamide</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 2/16 patients</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Grade 3/4 toxicities included neutropenia, anemia, constipation, peripheral neuropathy and venous thrombosis</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Dreicer et al. [<CitationRef CitationID="CR34_19">34</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>22 men with CRPC</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>100–200 mg/day</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>250 μg GM-CSF three times weekly</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>PSA decline of &gt;50% in 5/22 patients</SimplePara>
                      </entry>
                      <entry colname="c6">
                        <SimplePara>Grade 3/4 toxicities included neutropenia, fatigue, venous thrombosis and hyperglycemia</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">CRPC</Emphasis> castration-resistant prostate cancer; <Emphasis Type="Italic">DVT</Emphasis> deep vein thrombosis; <Emphasis Type="Italic">LMWH</Emphasis> low molecular weight heparin; <Emphasis Type="Italic">MTD</Emphasis> maximum tolerated dose; <Emphasis Type="Italic">PFS</Emphasis> progression free survival; <Emphasis Type="Italic">PSA</Emphasis> prostate-specific antigen</SimplePara>
                </tfooter>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Thalidomide Analogs</Heading>
            <Para TextBreak="No">Numerous thalidomide analogs have been synthesized to optimize the antiangiogenic and anti-tumor properties of thalidomide, while reducing the side effects [<CitationRef CitationID="CR39_19">39</CitationRef>]. This includes efforts to reduce teratogenticity, improve TNF-alpha inhibitory activity, or eliminate the need for metabolism. Of the thalidomide analogs currently in development, two agents in a class termed immunomodulatory drugs (IMiDs) have entered clinical testing. Lenalidomide (Revlimid<Superscript>®</Superscript>, CC-5013) and CC-4047 (Actimid<Superscript>®</Superscript>) act similarly to thalidomide, but have improved TNF-alpha inhibitory activity [<CitationRef CitationID="CR39_19">39</CitationRef>]. Initial in vitro and in vivo testing has suggested that lenalidomide possesses anti-migratory and anti-angiogenic activity [<CitationRef CitationID="CR40_19">40</CitationRef>]. It was shown to inhibit vascularization in a dose-dependent manner in the rat mesenteric window assay. Furthermore, endothelial cell migration was inhibited by lenalidomide in vitro [<CitationRef CitationID="CR40_19">40</CitationRef>]. In 2006, Lenalidomide was approved for use in combination with dexamethasone in patients with multiple myeloma by the US FDA.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Lenalidomide as a Single Agent</Heading>
            <Para TextBreak="No">A Phase I study of oral lenalidomide was initiated in 2002 by Dahut et al. [<CitationRef CitationID="CR41_19">41</CitationRef>]. Although open to any patient with a refractory solid tumor or lymphoma, 35 of the 45 patients accrued presented with prostate cancer. Lenalidomide was initially administered orally once per day continuously from 5 to 20 mg. This was subsequently modified, with patients receiving lenalidomide for the first 21 days of each 28-day cycle, starting at 15 mg/day and dose escalating to 40 mg/day. The most frequent grade 1 and 2 toxicities included fatigue, nausea, pruritus/rash, neutropenia, and neuropathy. Neutropenia was the most commonly observed grade 3/4 toxicity. SD was observed in a total of 12 patients, 9 of whom had prostate cancer. However, no durable PSA responses were noted [<CitationRef CitationID="CR41_19">41</CitationRef>].</Para>
            <Para TextBreak="No">In 2006, a randomized, double-blinded clinical study was initiated, enrolling patients with evidence of biochemical relapse following surgery or radiation [<CitationRef CitationID="CR42_19">42</CitationRef>]. Patients were randomized to receive either 5 or 25 mg/day of lenalidomide. An open-label phase II clinical trial was started in early 2008 to assess the toxicity and efficacy of lenalidomide in chemotherapy-naïve CRPC patients [<CitationRef CitationID="CR43_19">43</CitationRef>]. The drug is being administered orally at a dose of 25 mg/day for 21 days of each 28-day cycle. As of September 2008, both studies are continuing patient recruitment.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Lenalidomide in Combination Therapy</Heading>
            <Para TextBreak="No">Several combination studies with lenalidomide have been initiated, many of which are designed based on completed thalidomide trials, using lenalidomide in place of thalidomide. Lenalidomide is currently being evaluated in combination with ketoconazole, based on the hypothesis that the immune stimulatory activity might augment the activity of ketoconazole against prostate cancer in chemotherapy-naïve men with castrate-resistant disease [<CitationRef CitationID="CR44_19">44</CitationRef>]. Patients receive 25 mg/day oral lenalidomide on a 21 out of 28 day schedule, along with 400 mg ketoconazole three times daily continuously. As of May 2008, the study was still open to accrual. Toxicity has been reasonable, with fatigue commonly observed. Ten (56%) of the 18 evaluable patients had PSA declines of &gt;50%. Of the four individuals with measurable disease, three have achieved a partial response and the fourth has SD with tumor volume reduction [<CitationRef CitationID="CR44_19">44</CitationRef>].</Para>
            <Para TextBreak="No">A Phase I dose-finding study of lenalidomide in combination with docetaxel (based on the activity observed with thalidomide plus docetaxel) was initiated by Moss et al. [<CitationRef CitationID="CR45_19">45</CitationRef>]. As of early 2007, dosing has been escalated to 75 mg/m<Superscript>2</Superscript> docetaxel every 3 weeks, with an oral daily dose of lenalidomide up to 20 mg/day on days 1–14. No dose limiting toxicities had been observed and the MTD was not reached. Nine (47.4%) of the 19 evaluable patients experienced a PSA decline of &gt;50%. Of the 13 patients with measurable disease, 12 experienced a partial response or SD [<CitationRef CitationID="CR45_19">45</CitationRef>].</Para>
            <Para TextBreak="No">A combination study in men with metastatic CRPC who had previously received taxane therapy employed a 28-day lead-in of 10 mg lenalidomide (daily, 21/28 days) followed by the addition of weekly paclitaxel at 100 mg/m<Superscript>2</Superscript> [<CitationRef CitationID="CR46_19">46</CitationRef>]. Subsequent deescalation of the lenalidomide dose to 5 mg was necessary. In addition, five of the ten total patients enrolled discontinued therapy due to toxicity. Only one of the nine evaluable patients had a minor PSA decline during the lenalidomide lead-in. Overall, weekly paclitaxel combined with even low-dose lenalidomide was very poorly tolerated in this patient population [<CitationRef CitationID="CR46_19">46</CitationRef>].</Para>
            <Para TextBreak="No">Following on from the promising results of combining GM-CSF with thalidomide, a Phase I/II clinical trial was started with GM-CSF and lenalidomide in patients with CRPC [<CitationRef CitationID="CR47_19">47</CitationRef>]. Lenalidomide was administered daily at 25 mg/day on days 1–21 of each 28-day cycle. At an interim analysis, four of 17 evaluable patients had experienced a PSA decline of &gt;50%. Fatigue and diarrhea were the most common side effects observed [<CitationRef CitationID="CR47_19">47</CitationRef>].</Para>
            <Para TextBreak="No">Finally, a Phase II study of lenalidomide, ketoconazole, and hydrocortisone was opened in 2007 and is continuing to accrue men with CRPC [<CitationRef CitationID="CR48_19">48</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Summary</Heading>
            <Para TextBreak="No">Overall, thalidomide has demonstrated potentially promising activity against prostate cancer, especially in combination with cytotoxic or antiangiogenic agents. Activity has been observed both in earlier stage disease and in heavily pretreated populations of men with metastatic CRPC. Thalidomide appears to be altering the tumor microenvironment and may be working via several different mechanisms. However, it is apparent from the completed studies that the dose must be carefully determined in each regimen to minimize the toxicity. None of the published clinical studies of thalidomide have shown a benefit of doses of higher than 200 mg/day, and several have utilized 100 mg/day. Of particular concern is the occurrence of thromboembolic events, even with the administration of prophylactic anticoagulation, and the development of sensory neuropathy.</Para>
            <Para TextBreak="No">Initial results with lenalidomide are suggestive of activity in prostate cancer. To date, the most efficacious regimen appears to be the combination of lenalidomide with ketoconazole. In vitro and preclinical testing differs greatly between thalidomide and lenalidomide, and the two agents are likely working via different mechanisms of action. As such, different combinations may be required to achieve the best activity with each agent.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_19.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_19">
              <CitationNumber>1</CitationNumber>
              <BibUnstructured>Giving Thalidomide a Second Chance. 1997. (Accessed August 18, 2008, at <ExternalRef>
                  <RefSource>http://www.fda.gov/fdac/features/1997/697_thal.html</RefSource>
                  <RefTarget Address="http://www.fda.gov/fdac/features/1997/697_thal.html" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR2_19">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>D’Amato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Loughnan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Flynn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Thalidomide is an inhibitor of angiogenesis</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>4082</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>7513432</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.91.9.4082</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_19">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Bauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Dixon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent</ArticleTitle>
                <JournalTitle>Biochem Pharmacol</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>1827</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>9714301</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0006-2952(98)00046-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjvVehtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_19">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Lepper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Cox</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CD</Initials>
                  <FamilyName>Scripture</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Thalidomide metabolism and hydrolysis: mechanisms and implications</ArticleTitle>
                <JournalTitle>Curr Drug Metab</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>677</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>16918319</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2174/138920006778017777</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmvV2mtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 2006;7:677–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_19">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Lissbrant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Lissbrant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Damber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bergh</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer</ArticleTitle>
                <JournalTitle>Scand J Urol Nephrol</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>437</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>11848422</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1080/003655901753367532</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD387hsFGlug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35:437–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_19">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Siegal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Brawer</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Topography of neovascularity in human prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>75</VolumeID>
                <FirstPage>2545</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>7537624</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19950515)75:10&lt;2545::AID-CNCR2820751022&gt;3.0.CO;2-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M3lsVCntg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_19">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Flax</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Blumenfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688183</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szktlWqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_19">
              <CitationNumber>8</CitationNumber>
              <BibUnstructured>S.T.E.P.S. System for Thalidomide Education and Prescribing Safety. (Accessed August 18, 2008, at <ExternalRef>
                  <RefSource>http://www.thalomid.com/steps_program.aspx</RefSource>
                  <RefTarget Address="http://www.thalomid.com/steps_program.aspx" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR9_19">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Duray</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>1888</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>11448901</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlslaltbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_19">
              <CitationNumber>10</CitationNumber>
              <BibUnstructured>Dixon SC, Kruger EA, Bauer KS, Figg WD. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999;43 Suppl:S78–84. doi:<ExternalRef><RefSource>10.1007/s002800051103</RefSource><RefTarget Address="10.1007/s002800051103" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_19">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FM</Initials>
                  <FamilyName>Molloy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Floeter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NA</Initials>
                  <FamilyName>Syed</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Thalidomide neuropathy in patients treated for metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Muscle Nerve</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>1050</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11439380</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/mus.1109</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlvVemtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001;24:1050–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_19">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Drake</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Robson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mehta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Schofield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Neal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>822</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12644816</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6600817</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXitFegtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_19">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">A double blind randomized crossover study of oral thalidomide versus placebo in patients with androgen dependent prostate cancer treated by intermittent androgen ablation</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>181</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1104</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>19167733</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2008.11.026</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXjsVCgsro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Figg WD, Hussain MH, Gulley JL, et al. A double blind randomized crossover study of oral thalidomide versus placebo in patients with androgen dependent prostate cancer treated by intermittent androgen ablation. J Urol 2009;181(3):1104–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_19">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Efstathiou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Troncoso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>1224</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>17317833</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-1938</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhvF2hsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Efstathiou E, Troncoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007;13:1224–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_19">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_19">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Macarthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>O'Connor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>958</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>10071290</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhvFGgu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_19">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_19">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schultz</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>14</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604263</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVahtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:14–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_19">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>2532</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15226321</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.05.074</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWks7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_19">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1047</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>17437439</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2007.06763.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmvVaqsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Figg WD, Li H, Sissung T, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007;99:1047–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_19">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Frank</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Versea</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Long</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nair</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Low-dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide in androgen-independent prostate cancer (AIPC): final results of a phase II community based study in elderly men</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>15609</FirstPage>
              </BibArticle>
              <BibUnstructured>Frank R, Versea L, Cohen N, Long J, Nair K. Low-dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide in androgen-independent prostate cancer (AIPC): final results of a phase II community based study in elderly men. J Clin Oncol 2007;25:15609.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_19">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mathew</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Logothetis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PY</Initials>
                  <FamilyName>Dieringer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Genitourin Cancer</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>144</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>17026803</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2006.n.031</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFOmsr7M</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mathew P, Logothetis CJ, Dieringer PY, et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2006;5:144–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_19">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Amato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sarao</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Genitourin Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>281</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16729912</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2006.n.008</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xltlejsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Amato RJ, Sarao H. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin Genitourin Cancer 2006;4:281–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_19">
              <CitationNumber>24</CitationNumber>
              <BibUnstructured>Thalidomide and Doxil in Patients with Androgen Independent Prostate Cancer (AIPC). 2008. (Accessed August 25, 2008, at <ExternalRef>
                  <RefSource>http://www.clinicaltrials.gov</RefSource>
                  <RefTarget Address="http://www.clinicaltrials.gov" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR25_19">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Romero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Stanton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>DeFelice</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Schreiber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Rago</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fishman</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>284</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>17628293</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2006.09.017</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnslWlsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Romero S, Stanton G, DeFelice J, Schreiber F, Rago R, Fishman M. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol 2007;25:284–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_19">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Akakura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ueda</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>106</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12746834</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10231</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlslChurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Akakura K, Suzuki H, Ueda T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003;56:106–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_19">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Dakhil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Modiano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gregurich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Asmar</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>168</VolumeID>
                <FirstPage>2439</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441935</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)64163-8</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovVehsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_19">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Conaway</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>2506</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561316</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_19">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Saika</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kusaka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Tsushima</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients</ArticleTitle>
                <JournalTitle>Int J Urol</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>290</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>11389744</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1442-2042.2001.00302.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXltV2rtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 2001;8:290–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_19">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Storlie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Buckner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Wiseman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Burch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Hartmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Richardson</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>96</FirstPage>
                <LastPage>100</LastPage>
                <Occurrence Type="PID">
                  <Handle>8630883</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19950701)76:1&lt;96::AID-CNCR2820760114&gt;3.0.CO;2-E</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283it12qtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96–100.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_19">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stockler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1756</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8656243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslOrsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_19">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Lorenzo</FamilyName>
                  <Particle>Di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Autorino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Laurentiis</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial</ArticleTitle>
                <JournalTitle>Cancer Biol Ther</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>313</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17327701</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.4161/cbt.6.3.3664</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Di Lorenzo G, Autorino R, De Laurentiis M, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6:313–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_19">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Chung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kestell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Baguley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Ching</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>377</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>15060740</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00280-003-0753-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXivVCltb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chung F, Wang LC, Kestell P, Baguley BC, Ching LM. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemother Pharmacol 2004;53:377–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_19">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dreicer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Klein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Elson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Peereboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Byzova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EF</Initials>
                  <FamilyName>Plow</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>82</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15869991</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2004.08.013</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjslKgtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T, Plow EF. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 2005;23:82–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_19">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Amato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hernandez-McClain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Henary</FamilyName>
                </BibAuthorName>
                <Year>2009</Year>
                <ArticleTitle Language="En">Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>27</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>8</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>18367123</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2007.10.014</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhsFChtbzK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Amato RJ, Hernandez-McClain J, Henary H. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol 2009;27(1):8–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_19">
              <CitationNumber>36</CitationNumber>
              <BibUnstructured>Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer. (Accessed August 25, 2008, at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/ct2/show/NCT00450008</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/ct2/show/NCT00450008" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR37_19">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Laber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MI</Initials>
                  <FamilyName>Khan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GH</Initials>
                  <FamilyName>Kloecker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Schonard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Taft</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Salvador</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer</ArticleTitle>
                <JournalTitle>Cancer Biol Ther</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>840</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>17582215</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.4161/cbt.6.6.4099</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1yktrjK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol Ther 2007;6:840–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_19">
              <CitationNumber>38</CitationNumber>
              <BibUnstructured>Ning YM, Gulley JL, Arlen PM, et al. A phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070–6. doi:<ExternalRef><RefSource>10.1200/JCO.2009.25.4524</RefSource><RefTarget Address="10.1200/JCO.2009.25.4524" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_19">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Aragon-Ching</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Gardner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Thalidomide analogues as anticancer drugs</ArticleTitle>
                <JournalTitle>Recent Patents Anticancer Drug Discov</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>167</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.2174/157489207780832478</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXntlCqsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov 2007;2:167–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_19">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Dredge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Horsfall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Robinson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro</ArticleTitle>
                <JournalTitle>Microvasc Res</JournalTitle>
                <VolumeID>69</VolumeID>
                <FirstPage>56</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>15797261</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.mvr.2005.01.002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXis1Gqtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_19">
              <CitationNumber>41</CitationNumber>
              <BibUnstructured>Dahut W, Tohnya T, Aragon-Ching J, et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49(6):650–60. doi:<ExternalRef><RefSource>10.1177/0091270009335001</RefSource><RefTarget Address="10.1177/0091270009335001" TargetType="DOI"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_19">
              <CitationNumber>42</CitationNumber>
              <BibUnstructured>Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer. (Accessed August 26, 2008, at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/ct2/show/NCT00348595</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/ct2/show/NCT00348595" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR43_19">
              <CitationNumber>43</CitationNumber>
              <BibUnstructured>Phase II Study Evaluating Toxicity and Efficacy of Lenalidomide (Revlimid) in Chemotherapy-Naive Androgen Independent Prostate Cancer Patients. (Accessed 26 August, 2008, at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/ct2/show/NCT00654186</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/ct2/show/NCT00654186" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR44_19">
              <CitationNumber>44</CitationNumber>
              <BibUnstructured>Garcia J, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial. J Clin Oncol 2008;26:abstr 5143.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_19">
              <CitationNumber>45</CitationNumber>
              <BibUnstructured>Moss R, Mohile S, Shelton G, Melia J, Petrylak D. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). In: 2007 Prostate Cancer Symposium; 2007; Orlando, FL, Abstract 89.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_19">
              <CitationNumber>46</CitationNumber>
              <BibUnstructured>Pagliaro L, Tannir N, Tu S, et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol 2008;26:Abstract 13545.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_19">
              <CitationNumber>47</CitationNumber>
              <BibUnstructured>Dreicer R, Garcia J, Smith S, et al. Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC). J Clin Oncol 2007;25:Abstract 15515.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_19">
              <CitationNumber>48</CitationNumber>
              <BibUnstructured>Ketoconazole, Hydrocortisone, and Lenalidomide in Treating Patients with Prostate Cancer That Did Not Respond to Hormone Therapy. (Accessed August 26, 2008, at <ExternalRef>
                  <RefSource>http://clinicaltrials.gov/ct2/show/NCT00460031</RefSource>
                  <RefTarget Address="http://clinicaltrials.gov/ct2/show/NCT00460031" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
